Cargando…
Cysteine [2,4] Disulfide Bond as a New Modifiable Site of α-Conotoxin TxIB
α-Conotoxin TxIB, a selective antagonist of α6/α3β2β3 nicotinic acetylcholine receptor, could be a potential therapeutic agent for addiction and Parkinson’s disease. As a peptide with a complex pharmacophoric conformation, it is important and difficult to find a modifiable site which can be modified...
Autores principales: | Zhang, Baojian, Ren, Maomao, Xiong, Yang, Li, Haonan, Wu, Yong, Fu, Ying, Zhangsun, Dongting, Dong, Shuai, Luo, Sulan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7926623/ https://www.ncbi.nlm.nih.gov/pubmed/33671487 http://dx.doi.org/10.3390/md19020119 |
Ejemplares similares
-
Effects of Cyclization on Activity and Stability of α-Conotoxin TxIB
por: Li, Xincan, et al.
Publicado: (2020) -
Optimal Cleavage and Oxidative Folding of α-Conotoxin TxIB as a Therapeutic Candidate Peptide
por: Wu, Xiaosa, et al.
Publicado: (2013) -
α-Conotoxin TxIB Inhibits Development of Morphine-Induced Conditioned Place Preference in Mice via Blocking α6β2* Nicotinic Acetylcholine Receptors
por: Li, Xiaodan, et al.
Publicado: (2021) -
α-Conotoxin TxIB Improved Behavioral Abnormality and Changed Gene Expression in Zebrafish (Danio rerio) Induced by Alcohol Withdrawal
por: Mao, Kailin, et al.
Publicado: (2022) -
Molecular Determinants of Species Specificity of α-Conotoxin TxIB towards Rat and Human α6/α3β4 Nicotinic Acetylcholine Receptors
por: Xie, Ting, et al.
Publicado: (2023)